Susquehanna International Group, LLP Genocea Biosciences, Inc. Call Options Transaction History

Susquehanna International Group, LLP

11 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q2 2022 Aug 15, 2022	SELL	$0.01 - $1.38 $1,276 - $176,088	-127,600 Closed	0 $0
Q1 2022 May 16, 2022	SELL	$0.96 - $1.35 $12,576 - $17,685	-13,100 Reduced 9.31%	127,600 $160,000
Q4 2021 Feb 14, 2022	BUY	$0.95 - $1.99 $78,755 - $164,971	82,900 Added 143.43%	140,700 $163,000
Q3 2021 Nov 15, 2021	SELL	$1.74 - $2.33 $86,478 - $115,801	-49,700 Reduced 46.23%	57,800 $111,000
Q2 2021 Aug 11, 2021	SELL	$2.06 - $2.82 $164,182 - $224,754	-79,700 Reduced 42.57%	107,500 $252,000
Q1 2021 May 17, 2021	SELL	$2.35 - $4.01 $117,030 - $199,698	-49,800 Reduced 21.01%	187,200 $507,000
Q4 2020 Feb 16, 2021	BUY	$1.91 - $2.67 $176,102 - $246,174	92,200 Added 63.67%	237,000 $574,000
Q3 2020 Nov 16, 2020	BUY	$1.81 - $5.53 $202,539 - $618,807	111,900 Added 340.12%	144,800 $332,000
Q2 2020 Aug 14, 2020	BUY	$1.66 - $3.06 $37,848 - $69,768	22,800 Added 225.74%	32,900 $76,000
Q4 2019 Feb 14, 2020	SELL	$2.05 - $2.82 $15,989 - $21,996	-7,800 Reduced 43.58%	10,100 $21,000
Q2 2019 Nov 14, 2019	BUY	$3.47 - $6.71 $62,113 - $120,109	17,900 New	17,900 $70,000

10K

Ticker GNCA
Exchange OTC
Sector Healthcare
Industry Biotechnology
Shares Outstandng 58,783,500
Description
Genocea Biosciences, Inc., a biopharmaceutical company, discovers and develops novel cancer immunotherapies. The company uses its proprietary discovery platform, ATLAS, which profiles each patient's CD4+ and CD8+ T cell immune responses to every target or antigen identified by next-generation sequencing of that patient's tumor. Its products incl...

Get notified when there are updates to the investment portfolio of Susquehanna International Group, LLP, based on Form 13F filings with the SEC.

Stay updated on Susquehanna International Group, LLP with notifications on news.